Omar K. Abughanimeh, MBBS

Articles by Omar K. Abughanimeh, MBBS

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

ByOmar K. Abughanimeh, MBBS,Nicole A. Shonka, MD,Jane Meza, PhD,Lynette Smith, PhD,Irfan A. Vaziri, MD,Mehmet Sitki Copur, MD,Robin High, MBA,Kimberly Shields, BSN, RN,Holly DeSpiegelaere, BSN, RN,Anne Kessinger, MD,Apar Kishor Ganti, MD, MS

August 13th 2025

This study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.

Latest Updated Articles

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
August 13th 2025
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
October 30th 2025

Trending on CancerNetwork

177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment

DESTINY Trials May Reshape HER2-Positive Breast Cancer Care With T-DXd

BI-1808 Earns FDA Fast Track Status for Advanced Ovarian Cancer

Divesiran Shows Clinical Responses in Phase 2 Polycythemia Vera Trial

Disease Stage/Age Among Adverse Prognostic Factors for Ovarian Germ Cell Tumors